New molecules and vaccines: Peptide vaccines against HER2-low and MUC1 [147], a CSF1R inhibitor (altering the tumor microenvironment) [148], and STING agonists [149] are being investigated in clinical trials. This evidence concerns the gene ERBB2 and neoplasm.